{"nctId":"NCT01114529","briefTitle":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","startDateStruct":{"date":"2010-08-09","type":"ACTUAL"},"conditions":["Kidney Transplantation"],"count":828,"armGroups":[{"label":"Everolimus","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus"]},{"label":"Calcineurin inhibitor, Prograf or Neoral","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prograf or Neoral"]}],"interventions":[{"name":"Everolimus","otherNames":["Certican, Zortress, RAD001"]},{"name":"Prograf or Neoral","otherNames":["Tacrolimus or Cyclosporine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria at Baseline:\n\n* Male or female renal allograft recipients at least 18 years old.\n* Written informed consent.\n* Patient receiving a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor.\n* Cold ischemia time (CIT) \\< 24 hours.\n* Negative pregnancy test for female patients.\n\nInclusion Criteria at Randomization:\n\n* Patients on CNI (TAC or CsA) + Myfortic + steroids.\n* Serum creatinine \\< 2.8 mg/dL (250 µmol/L) and an actual eGFR (MDRD4) ≥ 25 mL/min/1.73m exp2 (without renal replacement therapy).\n\nExclusion Criteria at Baseline:\n\nPatients fulfilling any of the following criteria are not eligible for inclusion in this study:\n\n* Recipient of multiple organ transplants.\n* Recipient of ABO incompatible allograft or a positive cross-match.\n* Panel Reactive Antibodies (PRA) level ≥ 30 %.\n* Positive test for human immunodeficiency virus (HIV).\n* Patient receiving an allograft from a Hepatitis B surface Antigen (HBsAg) or a Hepatitis C Virus (HCV) positive donor.\n* HBsAg and/or a HCV positive patient with evidence of elevated LFTs (ALT/AST levels ≥ 2.5 times ULN).\n* Severe restrictive or obstructive pulmonary disorders.\n* Patient with severe allergy requiring acute or chronic treatment or hypersensitivity to any of the study drugs or similar drugs.\n* Severe hypercholesterolemia or hypertriglyceridemia.\n* Low platelet count.\n* Low white blood cell count.\n* History of malignancy of any organ system\n\nExclusion Criteria at Randomization:\n\n* Graft loss.\n* Patient on renal replacement therapy.\n* Patient who experienced severe humoral and/or cellular rejection (BANFF ≥ IIb).\n* Patient with ≥ 2 episodes of AR or an AR episode that needed antibody treatment.\n* Patient with ongoing or currently treated AR (2 weeks prior to randomization).\n* Proteinuria \\> 1 g/day.\n* Patients with recurrence of Focal Segmental Glomerulosclerosis (FSGS).\n* Low platelet count; Low white blood cell count; Low absolute neutrophil count; Low hemoglobin.\n* Severe liver disease.\n* Systemic infection requiring continued therapy that would interfere with the objectives of the study.\n* Severe hypercholesterolemia or hypertriglyceridemia.\n* Patients with ongoing wound healing problems, clinically significant infection requiring continued therapy.\n* Presence of intractable immunosuppressant complications or side effects.\n* Patients on anticoagulants that prevents renal allograft biopsy.\n* Use of prohibited medication.\n* Use of immunosuppressive agents not utilized in the protocol.\n* Pregnant or nursing (lactating) women.\n* Women of child-bearing potential not using a highly effective method of birth control.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Glomerular Filtration Rate (eGFR)","description":"Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \\[mL/min/1.73m˄2\\] = 186.3\\*(C˄-1.154)\\*(A˄-0.203)\\*G\\*R. DEFINITIONS: C = serum concentration of creatinine \\[mg/dL\\]; A = age \\[years\\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":"22.31"},{"groupId":"OG001","value":"61.5","spread":"19.86"},{"groupId":"OG002","value":"58.4","spread":"19.62"}]}]}]},{"type":"SECONDARY","title":"Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24","description":"Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\\*, (2) graft loss\\*\\*, or (3) death . \\*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \\*\\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24","description":"Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.30","spread":"11.62"},{"groupId":"OG001","value":"51.08","spread":"14.11"},{"groupId":"OG002","value":"51.13","spread":"12.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.95","spread":"12.63"},{"groupId":"OG001","value":"48.98","spread":"14.63"},{"groupId":"OG002","value":"50.96","spread":"13.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.66","spread":"12.19"},{"groupId":"OG001","value":"45.63","spread":"13.50"},{"groupId":"OG002","value":"47.91","spread":"12.71"}]}]}]},{"type":"SECONDARY","title":"Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)","description":"(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":188,"n":346},"commonTop":["Diarrhoea","Urinary tract infection","Leukopenia","Oedema peripheral","Pyrexia"]}}}